| | Business Summary | | Synthetic
Blood
International
Inc.
is
a
development-stage
company
that
is
developing
OXYCYTE,
a
proprietary
synthetic
blood
substitute
and
FLUOROVENT,
a
liquid
for
assisting
oxygen
exchange
in
damaged
or
diseased
lungs
based
upon
perfluorocarbon
technology.
In
addition
the
Company
has
developed
an
implantable
continuous
reading
glucose
biosensor
for
diabetics.
The
Company
is
now
in
the
preclinical
stage
and
is
completing
activities
necessary
for
the
preparation
of
applications
with
the
United
States
Food
and
Drug
Administration
(FDA)
to
begin
clinical
testing.
After
the
submission
to
the
FDA,
the
Company's
products
will
require
extensive
clinical
testing
before
FDA
approval
may
be
granted. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | SYBD
is
a
development-stage
company
which
is
developing
Oxycyte,
a
proprietary
synthetic
blood
substitute
and
Flourovent,
a
liquid
for
assisting
oxygen
exchange
in
damaged
or
diseased
lungs.
For
the
fiscal
year
ended
4/30/01,
the
Company
has
not
yet
realized
any
revenues.
Net
loss
increased
84%
to
$1.7
million.
Results
reflect
increased
research
and
development
expenses
due
to
the
addition
of
a
laboratory
in
California. | | More
from
Market Guide: Significant
Developments |
| | | | FY2001 Pay | |
| Roger Ekbom, 74
Chairman | -- | Robert Nicora, 61
Pres,
CEO | $158K | David Johnson, 54
CFO | -- | Richard Kiral, Ph.D., 60
VP-R&D | 144K | Robert Larsen, 72
Sec.,
Director | -- | | Dollar amounts are as of 30-Apr-2001 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/s/sybd.ob.gif)